Zymar and Hepatorenal syndrome - a phase IV clinical study of FDA data

Summary:

Hepatorenal syndrome is reported only by a few people who take Zymar.

The phase IV clinical study analyzes which people take Zymar and have Hepatorenal syndrome. It is created by eHealthMe based on reports of 653 people who have side effects while taking Zymar from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 05, 2022

653 people reported to have side effects when taking Zymar.
Among them, 4 people (0.61%) have Hepatorenal syndrome.


What is Zymar?

Zymar has active ingredients of gatifloxacin. eHealthMe is studying from 673 Zymar users for its effectiveness, alternative drugs and more.

What is Hepatorenal syndrome?

Hepatorenal syndrome (renal failure in patients with advanced chronic liver disease) is found to be associated with 822 drugs and 518 conditions by eHealthMe.

Number of Zymar and Hepatorenal syndrome reports submitted per year:

Could Zymar cause Hepatorenal syndrome?

Gender of people who have Hepatorenal syndrome when taking Zymar *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Hepatorenal syndrome when taking Zymar *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Zymar *:

  1. Bumetanide: 4 people, 100.00%
  2. Digoxin: 4 people, 100.00%
  3. Coumadin: 4 people, 100.00%
  4. Furosemide: 4 people, 100.00%
  5. Gemfibrozil: 4 people, 100.00%
  6. Lantus: 4 people, 100.00%
  7. Lopid: 4 people, 100.00%
  8. Lovenox: 4 people, 100.00%
  9. Lyrica: 4 people, 100.00%
  10. Cefotaxime: 4 people, 100.00%

Common side effects people have besides Hepatorenal syndrome *:

  1. Muscle Spasms (muscle contraction): 4 people, 100.00%
  2. Cardiac Failure Congestive: 4 people, 100.00%
  3. Hepatic Failure (liver failure): 4 people, 100.00%
  4. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 4 people, 100.00%
  5. Excoriation (to tear or wear off the skin of): 4 people, 100.00%
  6. Renal Failure Acute (rapid kidney dysfunction): 3 people, 75.00%
  7. Leukocytosis (increased white blood cells): 3 people, 75.00%
  8. Fever: 3 people, 75.00%
  9. Dizziness: 3 people, 75.00%
  10. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 75.00%

Common conditions people have *:

  1. Arrhythmias (irregular heartbeat): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zymar and have Hepatorenal syndrome?

Check whether Hepatorenal syndrome is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Hepatorenal syndrome and when was it recovered:

Expand to all the drugs that have ingredients of gatifloxacin:

Alternative drugs to, pros and cons of Zymar:

Hepatorenal syndrome treatments and more:

COVID vaccines that are related to Hepatorenal syndrome:

Common drugs associated with Hepatorenal syndrome:

All the drugs that are associated with Hepatorenal syndrome:

Common conditions associated with Hepatorenal syndrome:

All the conditions that are associated with Hepatorenal syndrome:

How the study uses the data?

The study uses data from the FDA. It is based on gatifloxacin (the active ingredients of Zymar) and Zymar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: